EST Cathie Wood’s ARK Investment bought 176K shares of Crispr Therapeutics (CRSP) todayDon't Miss our Black Friday Offers:Discover the ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

NOVEL molecular regulators of rheumatoid arthritis (RA) inflammation were presented as part of a plenary abstract session at ...

Rather than training the algorithm on content scraped from the internet, scientists trained the AI on nearly three million genomes.

The Evo can design DNA sequences to manipulate cell functions, create new genes, and even develop an entirely new CRISPR gene ...

As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM), the company has presented more ...

A virologist named Beata Halassy recently made headlines after publishing a report of successfully treating her own breast ...

Agricultural biotechnology is expected to significant growth in the coming years, driven by developments in gene-editing, ...

Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...